Banggood 15th Anniversary Sale Preview: Thousands of Lightning Deals for 48 Hours Starting on September 8

GUANGZHOU, China, Sept. 6, 2021 /PRNewswire/ — Banggood, a global leading online shop, has released details about some of the massive deals available for all users during the 48-hour-peak of its upcoming 15th Anniversary Sale. From 4:00 p.m. (UTC+8) on September 8 to 3:59 p.m. (UTC+8) on September 10, Banggood will release millions of items – from new gadgets and electronics to home and kitchen essentials and clothing – with big discounts and coupons. Additionally, during this period, users who pre-booked their favorite products with a $1 deposit can pay the balance to receive the lowest price.

Lightning Deals

To celebrate Banggood’s birthday on September 9, Banggood is offering a “$9.9 Bargain Dash” Lightning Deal on top-tier brands, categories, and products. Moreover, customers have a chance to win a Xiaomi Redmi Note 8 2021 for only $0.01. Deals might be snapped up in seconds, so visit Banggood Lightning Deals Center and set an alert before they sell out.

Hot Seller Must-Buy

Banggood’s featured Hot Seller Must-Buy is back with over 100,000 popular items from top brands such as Xiaomi and DJI. Shoppers just need to pay a deposit of $1 or $3 to book their favorite items, and then later pay the rest to get the lowest price. Deposit payments have been available since August 25, and the balance can be paid from 4:00 p.m. (UTC+8) on September 8 to 3:59 p.m. (UTC+8) on September 10 to get up to 80% off discount.


To say a giant thank-you to loyal customers, Banggood VIP members will enjoy exclusive shopping benefits during the 48-hour-peak. 50% discounts can be exchanged with VIP points and free shipping and shopping bonuses are also available. Anyone can register to join Banggood VIP to participate in VIP Day to get access to all the exclusive deals.

Since 2006, millions of customers have turned to Banggood to find the latest goods, including rare items from categories they are passionate about. As one of the most popular online shops globally, Banggood is continuously optimizing its supply chain, sourcing products directly from well-selected manufacturers and working closely with over 3,000 top quality brands. To celebrate the 15th anniversary, almost all these popular brands are participating in the sale for customers to shop for their passions at affordable prices on Banggood.


JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in China

  • The first CAR-T product independently developed in China and approved as a Category 1 biologics product, and the sixth approved CAR-T product globally
  • Currently the only approved CAR-T product that has been simultaneously included in the National Significant New Drug Development Program, granted priority review and breakthrough therapy designation
  • May provide a best-in-class CAR-T therapy in China given its demonstration of high rates of durable disease response and low rates of CAR-T associated toxicities

SHANGHAI, Sept. 6, 2021 /PRNewswire/ — JW Therapeutics (HKEx: 2126), an innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) of China has approved the New Drug Application (NDA) for its anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product relmacabtagene autoleucel injection (hereafter abbreviated as relma-cel, R&D code JWCAR029) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) after two or more lines of systemic therapy, and has released the drug registration certificate. Relma-cel is the first CAR-T product approved as a Category 1 biologics product in China, and sixth approved CAR-T product globally.

Relma-cel, JW Therapeutics’ first CAR-T product, was independently developed based on a CAR T cell process platform of Juno Therapeutics (a Bristol Myers Squibb company) to meet the needs of the Chinese market. Currently, it is the only approved CAR-T product in China that has been simultaneously included in the National Significant New Drug Development Program, granted priority review (in r/r LBCL) and breakthrough therapy designations (in follicular lymphoma). To date, over 100 patients have been dosed with relma-cel in clinical studies, marking relma-cel a most studied anti-CD19 CAR-T product in China.

This approval is based on the results of a single-arm, multi-center, pivotal study (RELIANCE study) to evaluate the efficacy and safety of relma-cel in patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) in China. RELIANCE study results show that relma-cel demonstrated high rates of durable disease response and low rates of CAR-T associated toxicities, and may provide a best-in-class CAR-T therapy profile.

Professor Zhu Jun, the lead investigator of RELIANCE study, Chief of Internal Medicine Department and Lymphoma Department at Peking University Cancer Hospital, said, “The RELIANCE study is a registrational clinical study completed with high quality, and I’m very proud of that. Based on the outstanding efficacy and safety profiles it demonstrated in RELIANCE study, I believe that relma-cel will provide healthcare professionals in China with an additional treatment option and bring hope for long-term remission and even cure for lymphoma patients.”

Edward Hu, Vice Chairman and Global Chief Investment Officer at WuXi AppTec, said, “Congratulations to JW Therapeutics for the approval of its first product. WuXi AppTec will continue to enable more companies to deliver advanced therapies for patients globally. Cell and gene therapy is one of the most promising therapies for curing cancer. As the co-founder and investor of JW Therapeutics, we are very pleased to witness its development over the past five years and are fully confident that JW Therapeutics will continue to lead the development of cell immunotherapy in China, and to bring us closer to a cure for cancer.”

Lynelle Hoch, senior vice president, Global Cell Therapy Franchise Lead, Bristol Myers Squibb, said, “As a long-standing strategic partner of JW Therapeutics, we are pleased by our work together to advance the important science of cell therapy. Today’s news, building from our CAR T cell process platform from Juno Therapeutics, marks an important milestone for patients in China and in achieving our shared goal of innovating breakthroughs for patients with cancer.”

James Li, Co-founder, Chairman and CEO of JW Therapeutics, said, “We sincerely thank all the patients and investigators who have participated and contributed in the clinical studies of relma-cel. We’re also encouraged by the Chinese regulators for taking the lead in following the science and approving the NDA of the sixth CAR-T therapy on a global scale. JW is committed to serving every Chinese patient through continued technology innovation.”


Zhu J, et al. Clinical Response of CD19 CAR-T Cells (relma-cel) in Adults with Heavily-Pre-Treated Relapsed/Refractory (r/r) Large B-Cell Lymphoma in China. ASH 2020. Abstracts 1186.

About Relmacabtagene Autoleucel Injection (trade name: Carteyva®)

Relmacabtagene autoleucel injection (trade name: Carteyva®) is an autologous anti-CD19 CAR-T cell immunotherapy products that was independently developed by JW Therapeutics based on a CAR T cell process platform of Juno Therapeutics (a Bristol Myers Squibb company). The first product of JW Therapeutics, relma-cel was approved by the China National Medical Products Administration (NMPA) in September 2021 for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, making it the first CAR-T product approved as a Category 1 biologics product in China. Currently, it is the only CAR-T product in China that has been simultaneously included in the National Significant New Drug Development Program, granted priority review and breakthrough therapy designations.

About RELIANCE Study (NCT04089215)

RELIANCE study was a single-arm, multi-center, pivotal study to evaluate the efficacy and safety of relmacabtagene autoleucel injection (relma-cel) in patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) in China. At the time it was conducted, this study was the largest clinical study of CAR-T cell therapy in China under the Investigational New Drug (IND) pathway.

RELIANCE study enrolled 59 patients with r/r LBCL who had failed at least two lines of therapy, including a CD20 agent and anthracycline, and patients continue to be monitored for up to 2 years and beyond for long term outcomes. As of the June 17, 2020 data cut-off, the Best Overall Response Rate was 75.9% with a Best Complete Response Rate of 51.7% in 58 evaluable patients; of 59 treated patients, 5.1% and 3.4% of the patients experienced CRS and NT of Grade 3 or above, respectively. Rates for any severity grade CRS and NT were 47.5% and 20.3%, respectively.

About JW Therapeutics

JW Therapeutics (HKEx: 2126) is an innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products. Co-founded by Juno Therapeutics (a Bristol Myers Squibb company) and WuXi AppTec in 2016, JW Therapeutics is committed to becoming an innovation leader in cell immunotherapy. The company has built a top world-class platform for technology and product development in cell immunotherapy, as well as a promising product pipeline covering both hematologic malignancies and solid tumors, to bring the hope of a cure for Chinese and global patients, and to lead the healthy and standardized development of China’s cell immunotherapy industry. For more information, please visit

Forward-Looking Statements

The forward-looking statements are based on the management’s expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described. Significant risks and uncertainties, include those discussed below and more fully described in Hong Kong Exchanges and Clearing Limited (HKEx) reports filed by the Company. Unless otherwise noted, the Company is providing this information as of the date it publicized, and expressly disclaims any duty to update information contained in the issues and relevant information, or provide any explanation. For detailed information, please visit the company website:

Universiti Teknologi PETRONAS Reigns as Malaysia’s Number 1 Private University in THE World University Rankings 2022

SERI ISKANDAR, Malaysia, Sept. 6, 2021 /PRNewswire/ — Universiti Teknologi PETRONAS (UTP) is the top ranking private university in Malaysia according to the Times Higher Education (THE) World University Rankings 2022 release, and successfully placed as second among Malaysian universities. In the latest rankings, the university has improved its position across three metrics, namely citations, research and international outlook.

UTP is the number one private university and second overall in Malaysia in the THE World University Rankings 2022

For the first time, UTP has broken into the 501-600 band, rising from its previous band of 601-800. This is by far the university’s highest achievement since its debut in 2017.

“This achievement is one of the testaments that UTP is very determined in delivering its commitment towards all our stakeholders especially our parent company PETRONAS, students, parents, sponsors and collaborators.

“UTP will continue its significant momentum as a leading university among our international peers by re-engineering our research strategic focus resulting in better impact on publications, by producing niche and value adding commercial applications and by converging more strategic partnerships with universities and industries within the region. As part of the PETRONAS group, we also see significant opportunities by aligning our initiatives to support PETRONAS’ current and future businesses as well as its sustainability agenda. We hope this will elevate our business outlook and strengthen our financial sustainability which will be crucial for the university’s future,” said UTP Vice Chancellor, Professor Ts. Dr Mohamed Ibrahim Abdul Mutalib.

“I wish to thank PETRONAS for the strong and unwavering support and to my team for their continuous dedication, hard work and perseverance which have taken us this far. Also, to the UTP community, namely our students and parents, for being with us in this journey through thick and thin,” he added.

UTP has continuously cemented its position as the best private university in the country, proven through consistently being ranked in the world and the nation rankings and ratings such as THE, Quacquarelli Symonds (QS), Malaysia Research Assessment Rating System (MyRA) and Rating System for Malaysian Higher Education (SETARA).

Notably, in the THE Asia University Rankings 2021, UTP is ranked 111th while for THE Young University Rankings 2021, the university is positioned at 134th. Meanwhile for QS, UTP is ranked 70th in the QS Asia University Rankings 2021. It is also ranked 230th in the QS World University Rankings by Subject 2021, where both its Petroleum Engineering and Mineral Engineering subjects are ranked in the Top 50 and the first in the nation. Furthermore, UTP has retained its six-star rating (the highest performance level) in MyRA for its research development and commercialisation programme. In addition, the university has achieved a six-star or outstanding status in SETARA for its teaching, research and services.

Photo –

الرئيس شي يحث المسؤولين الشباب على تعزيز الولاء والكفاءة للمهمات الأساسية

بكين، 6 أيلول/سبتمبر، 2021 / PRNewswire / — دعا الرئيس الصيني شي جنبنغ الأربعاء المسؤولين الشباب إلى تعزيز مثلهم، والبقاء مخلصين للحزب، واستخلاص الحقيقة من الوقائع وتحمل مسؤولياتهم والسعي ليصبحوا العمود الفقري لمجتمع يثق به الحزب والشعب للقيام بالمهمات الأساسية.

 أدلى شي بهذه التصريحات خلال كلمة ألقاها في افتتاح دورة تدريبية للمسؤولين الشباب ومتوسطي العمر في كلية الحزب التابعة للجنة المركزية للحزب الشيوعي الصيني، والمعروفة أيضًا باسم الأكاديمية الوطنية للحكم.

 وقال شي إن الحزب الشيوعي الصيني كان دائما حزبا سياسيا يحمل مُثُلا سامية وقناعة لا تقهر، مضيفا أن المثل والاعتقاد تشير إلى الإيمان بالماركسية، والمثل الأعلى للشيوعية، والمثل الأعلى المشتركة للاشتراكية ذات الخصائص الصينية.

 وقال إن بقاء الأعضاء مخلصين للحزب هو أفضل دليل على المثل والاعتقاد، مؤكدا أن هذا الولاء له مقياس واضح في الأوقات السلمية – التمسك بقيادة الحزب والحفاظ بحزم على سلطة اللجنة المركزية للحزب، فضلا عن القيادة المركزية والموحدة للجنة المركزية للحزب الشيوعي الصيني.

 وأكد شي على الحلول القائمة على الواقع، وحث المسؤولين الشباب على العمل في المستوى الابتدائي للتعرف على المزايا والعيوب، مع استيعاب كل من الثناء والنقد، حتى يتمكنوا من اكتساب فهم شامل للوضع الحقيقي.

 وأكد شي على الوفاء بالواجبات وتحمل المسؤوليات باعتباره ما يعطي قيمة للمسؤولين.

وقال شي إن التمسك بالمبادئ هو سمة شخصية مهمة للشيوعيين، ومعيار حاسم لتقييم كفاءة المسؤول، مضيفا أن جميع مسؤولي الحزب يجب أن يكونوا منصفين وعادلين في أداء واجباتهم وألا يتركوا مكانًا لمتابعة المصالح الشخصية في عملهم.

وحذر شي من المخاطر والتحديات المتزايدة بشكل كبير مع دخول التجديد الكبير للأمة الصينية فترة حرجة، وأبلغ شي المسؤولين الشباب بضرورة “التخلص من الأوهام والتجرؤ على النضال”. 

وقال: “يجب أن يتحلى الشيوعيون بالشخصية والنزاهة والشجاعة حتى لا تنخدعنا المغالطات أبدًا، ولا نرتعد أبدًا في مواجهة الخطر، وألا نكون جبناء وضعفاء أبدًا”.

 وحث شي المسؤولين الشباب على تبجيل الحزب والشعب والقانون والانضباط، ووضع الحزب والشعب دائما في صلب قلوبهم.


فيديو –

Growing Concerns Over Safety Reflect Increase in Second Citizenship Enquiries from Pakistanis

LONDON, Sept. 6, 2021 /PRNewswire/ — Over the last few weeks, London headquartered legal firm CS Global Partners has reported a significant increase in Pakistanis enquiring about attaining second citizenship through investment. The developments came as the country saw several acts of violence against women in a matter of weeks. The most recent incident involved an attack on a young woman at a national monument in Lahore on August 14.

Although Pakistan has seen progress in establishing peace within its borders, according to the Global Peace Index of 2021, the country still ranks 150 out of 163 countries in the world for its safety. Currently, parts of the country continue to face additional threats of terrorism, theft and political corruption.

Micha Emmett, the CEO of CS Global Partners, says that having access to physical and financial security is one of the top priorities for Pakistani clients. “Most citizens of Pakistan we speak to want second citizenship as a means to give their children a brighter, safer future. Citizenship from a country like St Kitts and Nevis can also open doors for their kids to choose from some of the best universities in the world without worrying about visitation visas and paperwork,” said Emmett.

St Kitts and Nevis has the longest-running Citizenship by Investment (CBI) Programme in the world. The Caribbean nation is surrounded by beautiful white sand beaches and acres of untouched nature and according to Emmett, is also a top choice for Pakistanis. The country allows vetted investors from Pakistan to become citizens from the comfort of their homes in a matter of months.

Under a limited-time offer that expires at the end of 2021, families of four get a USD45,000 price reduction from the Sustainable Growth Fund route. This option is praised for holding the fastest citizenship timeline by the PWM Magazine’s CBI Index. The report also noted St Kitts and Nevis’ robust due diligence process and family inclusivity for its ranking as the best CBI programme of 2021.

After successful applicants receive their Certificate of Citizenship, they can then apply for a passport with which visa-free and visa-on-arrival travel to nearly 160 countries and territories becomes a reality. “A second citizenship, a luxury that used to be reserved for the select few, has now become a necessity for many in this rapidly globalised world,” added Emmett.


‫‫معهد كالينجا للتكنولوجيا الصناعية (KIIT) يهيمن على التصنيف العالمي للجامعات

ويحصل على المركز الأول في أوديشا وشرق الهند

بوبانسوار، الهند، 6 سبتمبر 2021/ PRNewswire/- في إنجاز رائع، قفز معهد كالينجا للتكنولوجيا الصناعية (KIIT) بجامعة ديميد، بوبانسوار 200 مركزًا عالميًا ليتم وضعه في مجموعة 801-1000 في تصنيفات تايمز للتعليم العالي الخاص (THE)، وقد جاء الإعلان عنتصنيفات الجامعات العالمية في الثانيمن سبتمبر 2021. يُعد ذلك تحسنًا ملحوظًا عن العام الماضي عندما جاءت في المركز 1001+. وضع أداء معهد كالينجا للتكنولوجيا الصناعية (KIIT) الجامعة ذات المركز الأول في أوديشا وشرق الهند.

Campus 1

بينما تشترك معهد كالينجا للتكنولوجيا الصناعية (KIIT) ، والمعهد القومي للتكنولوجيا في روركيلا، وأمريتا فيشوا فيديابيثام، ومعهد فيلور للتكنولوجيا (VIT) في المرتبة ذاتها في الترتيب السنوي المُفضل والأكثر إحالة لمؤسسات التعليم العالي العالمية، كمّا تم تصنيف المعهد الهندي للتكنولوجيا في بوبانسوار وأكاديمية مانيبال للتعليم العالي في المرتبة 1000+. تراجع معهد سري راماسوامي التذكاري “SRM” للعلوم والتكنولوجيا إلى المرتبة +1200 مقارنة بمركزه في العام الماضي. لأنها جامعة حديثة الإنشاء، منذ 17 عامًا فقط، يُعد أداء معهد كالينجا للتكنولوجيا الصناعية (KIIT) أفضل من أي جامعة أخرى في البلاد. حيث حققت مراكز رائعة في الترتيب الذي أجرته مختلف الهيئات الحكومية.

 كمّا أعرب الدكتور: أشيوتا سامانتا، مؤسس معهد كالينجا للتكنولوجيا الصناعية  (KIIT)، ومعهد كالينجا للعلوم الاجتماعية (KISS)، عن سعادته بالجهود المشتركة التي بذلها الطلاب والموظفون لتحقيق هذا الإنجاز. “يُعد أداء معهد كالينجا للتكنولوجيا الصناعية (KIIT) في التصنيف ملحوظًا، حيث إنها جامعة متعددة التخصصات تضم ما يصل إلى 28 كلية. لو كانت مؤسسة تقدم دورات في الهندسة فقط، لكانت حققت مرتبة أعلى بكثير”. قال موظفو معهد كالينجا للتكنولوجيا الصناعية (KIIT) الذين يشعرون بالفخر بإن الأداء المتميز والمتواصل  لـمعهد كالينجا للتكنولوجيا الصناعية (KIIT) في التصنيفات العالمية والوطنية يرجع فقط إلى رؤية مؤسسها.

Campus 2

 تُعد تصنيفات تايمز للتعليم العالي (THE) الخاصة بالجامعات العالمية منشور سنوي لتصنيف الجامعات تصدره تايمز للتعليم العالي (THE). وهو عبارة عن جدول لأداء الجامعات العالمية الوحيد للحكم على الجامعات ذات عدد الأبحاث الكبير في جميع مهامها الأساسية. تشمل معايير التصنيف التدريس والبحث والاستشهادات ودخل الصناعة والتوقعات الدولية بالإضافة إلى عدد الطلاب، وعدد الطلاب لكل موظف، والطلاب الدوليين، ونسبة الطلاب والطالبات. يحظى التصنيف بثقة الطلاب والأكاديميين ورؤساء الجامعات والصناعة والحكومات في جميع أنحاء العالم.

 للتواصل الإعلامي:
شرادهنجالي ناياك